SFA Therapeutics is a clinical-stage biotech company based in New York, NY, that is revolutionizing the treatment of chronic inflammatory diseases. Their innovative approach involves deriving drugs from bacterial metabolites found in the human microbiome, resulting in faster clinical development, safer treatments, and no genotoxicity.
With a focus on over 85 chronic inflammatory diseases, including psoriasis, liver cancer, hepatitis B, and ophthalmic diseases, SFA Therapeutics aims to provide patients with safer and more effective treatment options. Their pipeline of microbiome-derived drugs offers a new platform for drug discovery and development, promising a new paradigm in the field of chronic inflammatory disease treatment.
Generated from the website